Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 13, Issue 3, 1999, Pages 27-36

  Ishizaki, T ^a   Horai, Y ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ISOENZYME; LANSOPRAZOLE; LIVER ENZYME; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

DRUG METABOLISM; DRUG TRANSFORMATION; GENETIC POLYMORPHISM; LIVER METABOLISM; PRIORITY JOURNAL; REVIEW;

EID: 0032807774     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00022.x     Document Type: Review

References (46)

1. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
2. Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 261-7.
3. Robinson M, Maton PN, Rodriguez S, Greenwood B, Humphries TJ. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 973-80.
4. Cloud ML, Enas N, Humphries TJ, Bassion S, The Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases. Results of three placebo-controlled dose - response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: 993-1000.
5. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - a European multicentre study. Aliment Pharmacol Ther 1998; 12: 789-95.
6. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
7. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8 (Suppl. 1): S21-5.
8. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.
9. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the, oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23.
10. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29: 619-24.
11. Horai Y, Ishizaki T. Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism. Rat Drug Ther 1988; 22: 1-8.
12. Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26: 753-9.
13. Bertilsson L. Geographic/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.
14. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773-80.
15. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57: 662-9.
16. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661-6.
17. Sanz EJ, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495-9.
18. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1988; 35: 167-71.
19. Edeki TI, Goldstein JA, de Morais SMF, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 1996; 6: 357 -60.
20. Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-97,
21. Sohn D-R, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52; 160-9.
22. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
23. de Morais SMF, Wilkinson GR, Blaisdell J. Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22.
24. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
25. Roh H-K, Dahl M-L, Tybring G, Yamada H, Cha Y-N, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996; 6: 547-51.
26. 1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 1998; 45: 27-9.
27. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-30.
28. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993; 266: 52-9.
29. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277; 805-16.
30. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article; the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
31. Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmncol Ther 1995; 58: 143-54,
32. VandenBranden M, Ring BJ, Binkley SN, Wrighton SA. Interaction of human liver cytochromes P450 in vitro with LY 307640, a gastric proton pump inhibitor. Pharmacogenetics 1996; 6: 81-91.
33. Chang M, Tybring G, Dahl M-L, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole: suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-8.
34. Sohn D-R, Kwon J-T, Kim H-K, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 1997; 61: 574-82.
35. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M, Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 1997; 52: 391-6.
36. Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997; 62: 619-28.
37. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole a gastric proton pump inhibitor on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-6.
38. Furuta T, Ohashi K, Takashima M, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH. Gastroenterology 1998; 114: A127 (Abstract).
39. Furuta T, Ohashi K, Kamata T, et al. CYP2C19 genotype status and dual therapy with omeprazole and amoxicillin for eradication of Helicobacter pylori and peptic ulcer healing. Gastroenterology 1998; 114: A127 (Abstract).
40. Flockhart DA. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin Pharmacokinet 1995; 29(Suppl. 1). 45-52.
41. Ko J-W, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-62.
42. Zech K, Steinijans VW, Huber R, Kolassa N, Radtke HW. Pharmacokinetics and drug interactions - relevant factors for the choice of a drug. Int J Clin Pharmacol Ther 1996; 34(Suppl.): S3-6.
43. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 1995; 58: 155-64.
44. Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
45. Humphries TJ, Nardi RV, Lazar JD. Spanyers SA. Drug drug interaction evaluation of rabeprazole sodium: a clean/ expected slate? Gut 1996; 39(Suppl. 3): A47 (Abstract).
46. Bottiger Y, Tybring G, Gotharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997; 62: 384-91.